Nanobiotix prices an oversubscribed EUR 85M global offering
Gross proceeds reached about $100M after the over-allotment was exercised.
16 events
Gross proceeds reached about $100M after the over-allotment was exercised.
Johnson & Johnson presented the data at the 2026 European Lung Cancer Conference.
A Nature study reaches pancreatic cells that LNPs could not reach before.
The LNP supplier adds mRNA construct design and manufacturing expertise.
The deal brings Generation Bio's cell-targeted LNP platform into XOMA's portfolio.
The SORT LNP developer also added a Praxis collaboration on ASO delivery.
Humboldt University chemists report the result in Science.
The change aligns the nanoparticle's status with the US and other major markets.
Capstan and Penn researchers report in vivo CAR-T generation in Science.
CHOP treated an infant with a rare inherited disorder; Acuitas contributed in kind.
The amendment strengthens Nanobiotix finances and extends cash visibility to mid-2026.
CSL and Arcturus vaccine uses LUNAR lipid-mediated delivery.
Manchester chemists show a motor transducing chemical energy through catalysis.
Penn engineers delivered VEGF mRNA to the placenta with tuned LNPs.
Nanobiotix's radioenhancing nanoparticle moves into a randomized lung cancer trial.
Programmable DNA strands couple or uncouple a microscopic motor's engine from its rotor.